Trial Profile
A randomized, double-blind, placebo-controlled study to evaluate the safety and effectiveness of DDP733 in female patients with irritable bowel syndrome with constipation
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Pumosetrag (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Dynogen Pharmaceuticals